Clinical Trials Sponsored by Durtol clinical center

Total 8771 results

National Cancer Institute (NCI)

Recruiting

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma | Liver Cancer

United States
National Cancer Institute (NCI)

Recruiting

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine Tumors | Neuroendocrine Neoplasms | Gastroenteropancreatico Tumors

United States
National Cancer Institute (NCI)

Recruiting

Pediatric cGVHD Symptom Scale

Graft vs Host Disease

United States, Canada
National Cancer Institute (NCI)

Recruiting

Children and Adults With Chordoma

Chordoma

United States
National Cancer Institute (NCI)

Recruiting

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Mesothelioma | Families

United States
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
National Cancer Institute (NCI)

Recruiting

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Small Cell Lung Cancer | Lung Cancer | Carcinoma, Small Cell

United States
National Cancer Institute (NCI)

Recruiting

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Metastatic Solid Tumors | Treatment-Refractory Cancers

United States
National Cancer Institute (NCI)

Recruiting

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Prostatic Hyperplasia | Prostate Cancer | Cancer Of Prostate | Prostatic Cancer | Prostatic Neoplams

United States
National Cancer Institute (NCI)

Recruiting

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Neuroendocrine Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Cervical Intraepithelial Neoplasia | Papillomavirus Infections | Vulvar Neoplasms | Vulvar Diseases | Carcinoma In Situ

United States
National Cancer Institute (NCI)

Recruiting

Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

Healthy Volunteer

United States
National Cancer Institute (NCI)

Recruiting

Collection of Tissue Blocks or Slides From Patients With Cancer

Cancer | Tumor | Benign Neoplasms | Carcinogens | Neoplasm, Benign

United States
National Cancer Institute (NCI)

Recruiting

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial Cancer

United States
National Cancer Institute (NCI)

Recruiting

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Prostate Cancer

United States
National Cancer Institute (NCI)

Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Breast Neoplasms | Colorectal Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

Healthy Volunteers | Bladder Cancer | Urothelial Cancer | Urinary Tract Cancer

United States
National Cancer Institute (NCI)

Recruiting

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Neoplasms | Myelodysplastic Syndromes | Lymphomas

United States
National Cancer Institute (NCI)

Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Extrapulmonary Small Cell Cancer | Pulmonary Neuroendocrine Tumors | Thymic Epithelial Tumors

United States
National Cancer Institute (NCI)

Recruiting

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Pleuropulmonary Blastoma | Cystic Nephroma | Nasal Chondromesenchymal Hamartoma | Ovarian Sertoli-Leydig Cell Tumors | Ocular Medulloepithelioma

United States
National Cancer Institute (NCI)

Recruiting

Apheresis of Patients With Immunodeficiency

DOCK8 | LAD-1 | GATA2 Deficancy

United States
National Cancer Institute (NCI)

Recruiting

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

DOCK8 Deficiency

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Metastatic Breast Carcinoma | Metastatic Ovarian Cancer | Metastatic Endocrine Tumors/ Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Recruiting

Collection of Blood From Patients With Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate

United States
National Cancer Institute (NCI)

Recruiting

A Study of Patients Receiving High-Dose Rate Brachytherapy

Cervical Cancer | Esophageal Cancer | Prostate Cancer | Endometrial Cancer | Biliary Cancer

United States
National Cancer Institute (NCI)

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Kidney Cancer | Bladder Cancer | Renal Cancer | Malignant Neoplasms | Hereditary Neoplastic Syndromes

United States
National Cancer Institute (NCI)

Recruiting

Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

Cancer

United States
National Cancer Institute (NCI)

Recruiting

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

HIV | Kaposi's Sarcoma | Primary Effusion Lymphoma | Lymphomas | Multicentric Castleman's Disease

United States
National Cancer Institute (NCI)

Recruiting

Evaluation for NCI Surgery Branch Clinical Research Protocols

Melanoma | Colorectal Cancer | Lung Cancer | Bladder Cancer | Synovial Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)

Parents of Children With Cancer | Parents of Children With NF1 | Parents of Children With Neurofibromatosis Type I

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Hormone Receptor-Positive Breast | Gynecologic | Desmoid | Hormone Receptor-Positive Neoplasms

United States
National Cancer Institute (NCI)

Completed

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

Leukemia | Multiple Myeloma | MGUS | Monoclonal B-Cell Lymphocytosis

United States
National Cancer Institute (NCI)

Enrolling by invitation

Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Melanoma | Adenocarcinoma | Neuroendocrine Tumors | Carcinoma NOS

United States
National Cancer Institute (NCI)

Enrolling by invitation

Data Collection, Clinical Care and Interventions in CCR, NCI

Neoplasms | Cancer

United States
National Cancer Institute (NCI)

Enrolling by invitation

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Cervical Intraepithelial Neoplasia | Oropharyngeal Neoplasms | Squamous Intraepithelial Lesions of the Cervix | Cervical Neoplasms | Hematologic Malignacies

United States
National Cancer Institute (NCI)

Enrolling by invitation

Nutrition Intervention Trials in Linxian Follow-up Study

Gastric Cancer | Esophageal Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

COVID-19

United States
National Cancer Institute (NCI)

Enrolling by invitation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Castrate Sensitive Prostate Cancer

United States
National Cancer Institute (NCI)

Enrolling by invitation

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Multiple Myeloma | Hematologic Malignancies | Leukemia, B-cell | Lyphoma, B-Cell

United States
National Cancer Institute (NCI)

Suspended

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Advanced Solid Tumors | SCLC | HRD Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

Brain Cancer | Brain Tumor | Neoplasm | Spine Cancer | Spine Tumor

United States
National Cancer Institute (NCI)

Enrolling by invitation

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Solid Tumors | Hematologic Malignancies | Pediatric Cancers

United States
National Cancer Institute (NCI)

Active, not recruiting

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
National Cancer Institute (NCI)

Enrolling by invitation

Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Primary Effusion Lymphoma | B-Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

Prostate Cancer

United States

Clinical Trials Sponsored by Durtol clinical center

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations